FOLFIRI联合雷莫西尤单抗对比紫杉醇联合雷莫西尤单抗用于既往接受或未接受多西他赛治疗的晚期或转移性胃食管腺癌二线治疗的II期RAMIRIS研究结果
这项多中心、研究者发起的II期RAMIRIS研究将既往含铂和氟尿嘧啶化疗失败的胃食管腺癌患者随机分配至FOLFIRI联合雷莫西尤单抗(A组)或紫杉醇联合雷莫西尤单抗(B组),主要终点为6个月总生存率(A组≥65%视为阳性信号)。A组6个月OS率为54%(95%CI 44-67),未达到主要终点;两组OS相似(HR 0.97,95%CI 0.62-1.52),A组ORR和PFS数值上更优(PFS HR 0.73;ORR 22% vs 11%)。
要点
- RAMIRIS研究未达到主要终点:FOLFIRI联合雷莫西尤单抗组6个月OS率为54%(95%CI 44-67),低于预设的65%阳性信号阈值。
- 两组总生存相似(HR 0.97,95%CI 0.62-1.52),FOLFIRI联合雷莫西尤单抗组ORR和PFS数值上更优(PFS HR 0.73;ORR 22% vs 11%)。
- 在既往接受多西他赛治疗的患者中,FOLFIRI联合雷莫西尤单抗组显示出更有利的疗效(HR 0.49;ORR 25% vs 8%)。
核心结论
- RAMIRIS研究证实FOLFIRI联合雷莫西尤单抗方案可行;虽然研究正式结果为阴性,但为进一步研究该联合方案用于既往接受多西他赛治疗的患者提供了信号。
研究设计与样本
- 多中心、研究者发起的II期随机对照试验,将胃食管腺癌患者随机分配至FOLFIRI联合雷莫西尤单抗(A组)或紫杉醇联合雷莫西尤单抗(B组),主要终点为6个月总生存率。
- 共入组111例患者(65%既往接受过多西他赛),110例纳入意向治疗人群(A组72例,B组38例)。
- 安全性人群共106例。
主要发现
- A组6个月OS率为54%(95%CI 44-67),未达到与历史对照比较的主要终点。
- 两组间OS相似(HR 0.97,95%CI 0.62-1.52),A组ORR和PFS数值上优于B组(PFS HR 0.73;ORR 22% vs 11%)。
- 上述差异主要归因于A组在既往多西他赛治疗患者中的有利疗效结果(HR 0.49;ORR 25% vs 8%)。
- 安全性人群中,3-5级不良事件两组相似(A组75%;B组68%)。
关键数值与推荐
- 主要终点为6个月OS率,A组≥65%视为进一步研究的阳性信号。
- A组6个月OS率为54%(95%CI 44-67)。
- 两组OS的HR为0.97(95%CI 0.62-1.52)。
- PFS的HR为0.73;ORR为A组22% vs B组11%。
- 既往多西他赛治疗患者中HR为0.49;ORR为A组25% vs B组8%。
临床怎么用
- 原文结论指出RAMIRIS研究证实FOLFIRI联合雷莫西尤单抗方案可行。
- 原文结论指出虽然研究正式为阴性,但为进一步研究该联合方案用于既往接受多西他赛治疗的患者提供了信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ramucirumab and paclitaxel is the standard second-line therapy in patients with metastatic gastroesophageal adenocarcinoma. We report the efficacy and safety analyses of FOLFIRI and ramucirumab versus paclitaxel and ramucirumab after the failure of a platinum- and fluoropyrimidine-containing chemotherapy. METHODS: This multicenter, investigator initiated, phase II trial randomised patients with gastroesophageal adenocarcinoma to either FOLFIRI plus ramucirumab (RAM) (arm A) or paclitaxel plus RAM (arm B). The primary end-point was 6-month overall survival (OS) rate, with a proportion of ≥65% in arm A considered a positive signal for further investigation. RESULTS: 111 patients (65% of patients had prior docetaxel) were enrolled and 110 patients qualified for ITT population (arm A, 72; arm B, 38). The study did not meet the primary end-point for the comparison with historical control, as 6-month OS rate in the FOLFIRI plus RAM arm was 54% (95% CI 44-67). In between arm comparison, OS was similar (hazard ratio, HR 0.97 [95% CI 0.62-1.52]), while objective response rates (ORRs) and PFS were numerically better in arm A versus arm B (HR for PFS 0.73; ORR, 22% versus 11%). These differences were largely attributed to favourable efficacy results for arm A in docetaxel-pretreated patients (HR, 0.49; ORR, 25% versus 8%). In the safety population (n = 106), grade 3-5 adverse events were similar between arms (arm A, 75%; arm B, 68%). CONCLUSION: The RAMIRIS trial demonstrated feasibility of FOLFIRI plus RAM. While the study was formally negative, it provided a signal to further investigate this combination for the group of patients with previous docetaxel therapy. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT03081143.
引用
- Lorenzen S, Thuss-Patience P, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022. PMID: 35202974. doi:10.1016/j.ejca.2022.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。